Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
DOS · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| DOS (Docetaxel, Oxaliplatin and S-1) | EXPERIMENTAL | Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period) |
| Name | Type | Description |
|---|---|---|
| DOS (Docetaxel, Oxaliplatin and S-1) | DRUG | Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period) |
Inclusion Criteria: * Histologically confirmed gastric adenocarcinoma, initially diagnosed or recurred * Unresectable, locally advanced or metastatic * At least one uni-dimensional measurable lesion by RECIST criteria * Age 18 to 70 years old * ECOG performance status ≤2 * Estimated life expectancy...
DOS is a three-drug combination regimen of docetaxel, oxaliplatin and S-1, also written as DOS (Docetaxel, Oxaliplatin and S-1). It is an investigational small molecule oncology regimen developed by Sanofi (ticker SNY) and studied in stomach neoplasms, also called gastric cancer. The combination has been evaluated in a Phase 2 trial.
DOS was studied for advanced gastric cancer, the condition listed as stomach neoplasms. The regimen combines docetaxel, oxaliplatin and S-1 and was tested in a Phase 2 trial of 44 participants with advanced gastric cancer in South Korea. It is investigational and not an approved therapy.
Sanofi, which trades under the ticker SNY, is the developer of the DOS regimen. DOS stands for the combination of docetaxel, oxaliplatin and S-1, three small molecule agents given together. Sanofi sponsored the Phase 2 study of the regimen in advanced gastric cancer.
DOS is in Phase 2 development. The only listed trial of the regimen, NCT00525005, was a Phase 2 study titled Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer. That trial is completed, and no active trials of DOS are currently listed.
DOS has been studied in one clinical trial, NCT00525005, titled Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer. It was a Phase 2, uncontrolled, non-randomized study that enrolled 44 participants aged 18 years and older in South Korea. The trial is completed.